You are here: Industry Insights > Covaxin

News List

India approves $610 million grant for Serum Institute, Bharat Biotech to boost vaccine production capacity expresspharma
April 21, 2021
India’s government has approved a 45.67-billion-rupee ($610 million) grant for COVID-19 vaccine makers Serum Institute of India (SII) and Bharat Biotech to boost production capacity as infections spread at record speed, its finance minister said.
Bharat Biotech announces COVAXIN capacity expansion expresspharma
April 21, 2021
Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for COVAXIN.
Haffkine Bio-Pharma to target 22.8 crore Covaxin vials annually expresspharma
April 19, 2021
After receiving permission to make Bharat Biotech’s COVID-19 vaccine Covaxin, Haffkine Bio-Pharmaceutical said it would take least at one year’s time for the company to start actual production.
PSUs roped in to ramp up COVID-19 vaccine production expresspharma
April 19, 2021
The production of indigenously developed COVID-19 vaccine Covaxin will be ramped up significantly and increased to 10 crore doses per month by September, the Department of Biotechnology said.
Manufacture of Indian vaccine in Russia cannot be ruled out: Russian Foreign Minister expresspharma
April 08, 2021
The RDIF has signed contracts with several Indian contractors to manufacture the Sputnik V vaccine to the tune of 700-750 million doses.
DCGI expert committee allows clinical trials for third dose of Bharat Biotech’s Covaxin expresspharma
April 06, 2021
The expert panel of DCGI has permitted Bharat Biotech to give a third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine, sources said.
Anvisa says Covaxin producing facility does not meet CGMP standards expresspharma
April 01, 2021
The Brazilian health regulator Anvisa has denied permission to import Bharat Biotech’s COVID-19 vaccine Covaxin into the country after its authorities found that the plant in which the vaccine is being made did not meet the Current Good Manufacturing ...
Interval between two doses of COVISHIELD increased to 4-8 weeks expresspharma
March 23, 2021
Protection enhanced if the second dose of COVISHIELD is administered between 6-8 weeks, says NTAGI and NEGVAC.
Bharat Biotech announces Phase 3 results of COVAXIN®: India's first COVID-19 vaccine demonstrates interim clinical efficacy of 81% worldpharmanews
March 22, 2021
Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, announced the first interim analysis of its BBV152 (COVAXIN®).
Maha wants to manufacture Covaxin at Haffkine: Rajesh Tope expresspharma
March 19, 2021
Maharashtra Health Minister Rajesh Tope said the state government wants to manufacture the Covaxin vaccine against COVID-19 at Mumbai’s Haffkine Institute.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page